Altogether, these results suggested that miR-31 might act as a biomarker in ESCC and a novel functional axis of miR-31/LATS2/TAZ might propose a feasible therapeutic approach for ESCC that merited further evaluation. The gene discussed is LATS2; the disease is esophageal squamous cell carcinoma.